Interventions are actions taken by or for individuals to reduce the risk, duration, or severity of adverse health conditions. Interventions may be population-based or personal.
DCP2 and GBD present what we know about which health interventions work for a comprehensive range of diseases, injuries, and disabilities in many different contexts. A large share of the disease burden in low- and middle-income countries is attributable to diseases and conditions for which cost-effective interventions are already known and feasible. Selecting the right intervention for a given disease and context matters a great deal. The tools on this page are designed to aid the task.
DCP2 and GBD demonstrate how decision makers could use cost-effectiveness information in combination with information on disease prevalence and avertable illness to determine which interventions should be extended and which ones should be questioned. If developing countries scale up interventions and extend health care services that are cost-effective, the impact on the disease burden could be substantial.
Select Criteria
Download Results (CSV)
|
Download Full Data Set (XLS)
| Condition |
Intervention
|
Intervention type
|
Intervention description |
Intervention setting
|
Objective
|
Target population
|
Cost effectiveness
(US$/DALY)
|
Cost effectiveness estimate
(US$)
|
Cost effectiveness range
(US$/DALY)
|
Number of DALYs averted
(hundreds)
|
Number of deaths averted
(hundreds)
|
Quality of cost-effectiveness analysis evidence
|
|
Schizophrenia
|
Antipsychotic drugs with optional psychosocial treatment, communitybased |
Personal |
Maintenance treatment in a community-based setting with antipsychotic drugs, neuroleptic antipsychotic drug, or an atypical antipsychotic drug, with or without psychosocial treatment |
Community
|
secondary prevention
|
Adults, Adolescents and adults
|
9,834 |
- |
2,472-17,197 |
0.7 |
-- |
5 |
|
Schizophrenia
|
Antipsychotic drugs with optional psychosocial treatment, hospitalbased |
Personal |
Maintenance treatment in a hospital setting with antipsychotic drugs, neuroleptic antipsychotic drug, or an atypical antipsychotic drug, with or without psychosocial treatment |
Local or district hospital, Referral hospital
|
secondary prevention
|
Adults, Adolescents and adults
|
11,920 |
- |
4,105-19,736 |
0.6 |
-- |
5 |
|
Depression
|
Drugs with optional episodic or maintenance psychosocial treatment |
Personal |
Antidepressant drugs (tricyclic antidepressant or selective serotonin reuptake inhibitor) used alone or in combination with psychosocial treatment for episodic depression or maintenance treatment |
Local or district hospital, Referral hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
1,699 |
- |
657-2,741 |
3.96 |
-- |
5 |
|
Panic disorder
|
Drugs with optional psychosocial treatment |
Personal |
Anxiolytic drugs (benzodiazepine), tricyclic antidepressants or selective serotonin reuptake inhibitor used with or without psychosocial treatment |
Local or district hospital, Referral hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
734 |
- |
384-1,084 |
0.83 |
-- |
5 |
|
Bipolar disorder
|
Lithium, valproate, with optional psy-chosocial treatment, community-based |
Personal |
Episodic treatment of bipolar disorder in a community setting using lithium or valproate with or without maintenance or episodic psychosocial treatment |
Local or district hospital, Referral hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
3,113 |
- |
2,498-3,728 |
1.35 |
-- |
5 |
|
Bipolar disorder
|
Lithium, valproate, with optional psychosocial treatment, hospital-based |
Personal |
Episodic treatment in a hospital setting with lithium or valproate with or without maintenance or episodic psychosocial treatment |
Local or district hospital, Referral hospital
|
secondary prevention
|
Adults, Women of childbearing age, Adolescents and adults
|
4,417 |
- |
3,590-5,244 |
1 |
-- |
5 |
Download Results (CSV)
|
Download Full Data Set (XLS)
|